Research Topics
Species | D MischoulonSummaryAffiliation: Massachusetts General Hospital Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Omega-3 fatty acids in psychiatryDavid Mischoulon
Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 1 Bowdoin Square, 6th Floor, Boston, MA 02114, USA
Psychiatr Clin North Am 36:15-23. 2013....- Prevalence of MTHFR C677T and MS A2756G polymorphisms in major depressive disorder, and their impact on response to fluoxetine treatmentDavid Mischoulon
Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
CNS Spectr 17:76-86. 2012..To examine the prevalence of the C677T polymorphism of the methylene tetrahydrofolate reductase (MTHFR) gene and the A2756G polymorphism of methionine synthase (MS), and their impact on antidepressant response... - Bioavailability of S-adenosyl methionine and impact on response in a randomized, double-blind, placebo-controlled trial in major depressive disorderDavid Mischoulon
Massachusetts General Hospital, Boston, MA 02114, USA
J Clin Psychiatry 73:843-8. 2012.... - Efficacy of dose increase among nonresponders to low-dose aripiprazole augmentation in patients with inadequate response to antidepressant treatment: a randomized, double-blind, placebo-controlled, efficacy trialDavid Mischoulon
Depression Clinical and Research Program, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
J Clin Psychiatry 73:353-7. 2012.... 
Update and critique of natural remedies as antidepressant treatmentsDavid Mischoulon
Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Suite 401, Boston, MA 02114, USA
Obstet Gynecol Clin North Am 36:789-807, x. 2009..There are limited data regarding safety in pregnancy and during lactation, and caution is therefore recommended in women who are pregnant or breastfeeding...- A double-blind dose-finding pilot study of docosahexaenoic acid (DHA) for major depressive disorderDavid Mischoulon
Depression Clinical and Research Program, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, United States
Eur Neuropsychopharmacol 18:639-45. 2008..05). For completers and intent-to-treat subjects, plasma DHA increased significantly (p<0.05), EPA had little change (p>0.05), and n-6/n-3 decreased significantly (p<0.05). DHA may be effective for depression at lower doses... 
Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of cliniciansD Mischoulon
Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA
Can J Psychiatry 45:476-81. 2000..To examine treatment practices in cases where selective serotonin reuptake inhibitors (SSRIs) are ineffective...- Report of two double-blind randomized placebo-controlled pilot studies of a carbohydrate-rich nutrient mixture for treatment of seasonal affective disorder (SAD)David Mischoulon
Clinical Research Center, Massachusetts Institute of Technology, Cambridge, MA, USA
CNS Neurosci Ther 16:13-24. 2010..The drink mix was well tolerated and treatment adherence was high. Both the active and placebo intervention were effective in alleviating symptoms of SAD. Replication studies in larger samples appear warranted... - A double-blind, randomized controlled trial of ethyl-eicosapentaenoate for major depressive disorderDavid Mischoulon
Massachusetts General Hospital, Depression Clinical and Research Program, Boston, MA 02114, USA
J Clin Psychiatry 70:1636-44. 2009..To examine the efficacy and tolerability of ethyl-eicosapentaenoate (EPA-E) monotherapy for major depressive disorder (MDD)... - The role of folate in depression and dementiaDavid Mischoulon
Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
J Clin Psychiatry 68:28-33. 2007..Supplementation with the active form of folate, methyltetrahydrofolate, which is more readily absorbed, may be effective in the prevention and treatment of both depression and dementia... - "The Matrix": An allegory of the psychoanalytic journeyDavid Mischoulon
Harvard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA
Acad Psychiatry 28:71-7. 2004..quot;The Matrix" has been a huge commercial and critical success and has spawned a series of books and essays exploring the philosophical and religious themes in the story... - Update and critique of natural remedies as antidepressant treatmentsDavid Mischoulon
Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, WAC 812, 15 Parkman Street, Boston, MA 02114, USA
Psychiatr Clin North Am 30:51-68. 2007..Finally, as with all psychotropic agents, natural medications should be used preferably under the supervision of a physician... - Anemia and macrocytosis in the prediction of serum folate and vitamin B12 status, and treatment outcome in major depressionD Mischoulon
Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, 15 Parkman St, WAC 812, Boston, MA 02114, USA
J Psychosom Res 49:183-7. 2000..We wished to determine whether anemia or macrocytosis predict hypofolatemia, low B12, or refractoriness to antidepressants... - Management of major depression in the primary care settingD Mischoulon
Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA, USA
Psychother Psychosom 70:103-7. 2001..We wished to determine how PCPs in a community clinic setting initially manage patients newly diagnosed with major depression... - Role of S-adenosyl-L-methionine in the treatment of depression: a review of the evidenceDavid Mischoulon
Harvard Medical School, Depression Clinical and Research Program, Massachusetts General Hospital, Boston 02114, USA
Am J Clin Nutr 76:1158S-61S. 2002..Head-to-head comparisons with newer antidepressants should help to clarify SAMe's place in the psychopharmacologic armamentarium... - An open pilot study of nefazodone in depression with anger attacks: relationship between clinical response and receptor bindingDavid Mischoulon
Department of Psychiatry, Massachusetts General Hospital, 15 Parkman Street, WAC 812, Boston, MA 02114, USA
Psychiatry Res 116:151-61. 2002..The effectiveness of nefazodone for depression with anger attacks may be related to widespread changes in 5HT2 receptor BP... - Depression and eating disorders: treatment and courseDavid Mischoulon
Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
J Affect Disord 130:470-7. 2011..We examined the course of major depressive disorder (MDD) and predictors of MDD recovery and relapse in a longitudinal sample of women with eating disorders (ED)... - Clinical and sociodemographic predictors of response to augmentation, or dose increase among depressed outpatients resistant to fluoxetine 20 mg/dayR H Perlis
Depression Clinical and Research Program, Massachusetts General Hospital, WACC 812, 15 Parkman Street, Boston, MA 02114, USA
Acta Psychiatr Scand 108:432-8. 2003..Factors moderating response to these next-step interventions are not well-studied... - The potential relationship between levels of perceived stress and subtypes of major depressive disorder (MDD)A H Farabaugh
Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA WAC 812, USA
Acta Psychiatr Scand 110:465-70. 2004.... - A preliminary open study of the tolerability and effectiveness of nefazodone in major depressive disorder: comparing patients who recently discontinued an SSRI with those on no recent antidepressant treatmentDavid Mischoulon
Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts
Depress Anxiety 19:43-50. 2004..Our study suggests that the rate of negative outcomes with nefazodone is no different whether patients have recently failed an SSRI... - Frontal EEG predictors of treatment outcome in major depressive disorderDan V Iosifescu
Depression Clinical and Research Program, Massachusetts General Hospital, and Harvard Medical School, Boston, MA 02114, United States
Eur Neuropsychopharmacol 19:772-7. 2009..To investigate the role of frontal EEG as predictor of clinical response to SSRIs or venlafaxine in major depressive disorder (MDD)... - A double-blind, randomized, pilot dose-finding study of maca root (L. meyenii) for the management of SSRI-induced sexual dysfunctionChristina M Dording
Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
CNS Neurosci Ther 14:182-91. 2008..Maca was well tolerated. Maca root may alleviate SSRI-induced sexual dysfunction, and there may be a dose-related effect. Maca may also have a beneficial effect on libido... - A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depressionMaurizio Fava
Depression Clinical and Research Program, Massachusetts General Hospital, 55 Fruit St, Bulfinch 351, Boston, MA 02114, USA
J Clin Psychiatry 72:473-9. 2011..In this post hoc analysis of patients with insomnia and comorbid anxious depression, eszopiclone cotherapy with a selective serotonin reuptake inhibitor (SSRI) was compared with placebo cotherapy... - Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorderGeorge I Papakostas
Depression Clinical and Research Program at Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Psychiatry Res 161:116-20. 2008..Studies examining whether specific treatment strategies are more effective than the selective serotonin reuptake inhibitors for MDD patients with high levels of co-morbid psychic and somatic anxiety symptoms are warranted... - Vagus nerve stimulation: 2-year outcomes for bipolar versus unipolar treatment-resistant depressionAndrew A Nierenberg
Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Biol Psychiatry 64:455-60. 2008..This study describes the outcome of VNS for bipolar TRD patients participating in the acute and longitudinal pivotal trials and compares their outcome with unipolar TRD patients in the same trials... - The overlap between personality disorders and major depressive disorder (MDD)Amy Farabaugh
The Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
Ann Clin Psychiatry 16:217-24. 2004..Research studies have focused attention on the importance of the comorbidity of personality disorders and depression... - Cholesterol in mood and anxiety disorders: review of the literature and new hypothesesGeorge I Papakostas
Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, 15 Parkman Street, WACC 812, Boston, MA 02114, USA
Eur Neuropsychopharmacol 14:135-42. 2004..We then propose possible mechanisms that would account for the relationship between elevated cholesterol and treatment non-response in MDD... - Folate in depression: efficacy, safety, differences in formulations, and clinical issuesMaurizio Fava
Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, 55 Fruit Street, Bulfinch 351, Boston, MA 02114, USA
J Clin Psychiatry 70:12-7. 2009..Several forms of folate appear to be safe and efficacious in some individuals with major depressive disorder, but more information is needed about dosage and populations most suited to folate therapy... - Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatmentAmy Farabaugh
Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA USA
Ann Clin Psychiatry 22:166-71. 2010.... - S-adenosyl methionine (SAMe) augmentation of serotonin reuptake inhibitors for antidepressant nonresponders with major depressive disorder: a double-blind, randomized clinical trialGeorge I Papakostas
Center for Treatment Resistant Depression, Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 15 Parkman St, Boston, MA 02114, USA
Am J Psychiatry 167:942-8. 2010.... - Deficits in psychological well-being and quality-of-life in minor depression: implications for DSM-VAndrew A Nierenberg
Bipolar Clinic and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
CNS Neurosci Ther 16:208-16. 2010..To examine deficits in psychological well-being (PWB) and quality-of-life (QOL) in minor depressive disorder (Min D)... - Low-dose transdermal testosterone augmentation therapy improves depression severity in womenKaren K Miller
Neurendocrine Research Program in Women s Health, Neuendocrine Unit, Massachusetts General Hospital, Boston, MA, USA
CNS Spectr 14:688-94. 2009..Conclusion: These preliminary pilot data suggest that low-dose transdermal testosterone may be an effective augmentation therapy in women with treatment-resistant depression. Further studies are warranted. CNS Spectr. 2009;14(12):688-694.. - Complementary and alternative medicine in major depressive disorder: the American Psychiatric Association Task Force reportMarlene P Freeman
Center for Women s Mental Health, Massachusetts General Hospital, Boston, MA 02114, USA
J Clin Psychiatry 71:669-81. 2010..To review selected complementary and alternative medicine (CAM) treatments for major depressive disorder (MDD)... - Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressantsMarlene P Freeman
Perinatal and Reproductive Psychiatry Program, Massachusetts General Hospital, 185 Cambridge St, 2nd Floor, Boston, MA 02114, USA
J Clin Psychiatry 71:682-8. 2010.... - Evidence for folate in combination with antidepressants at initiation of therapyMaurizio Fava
Department of Psychiatry, Harvard Medical School and Massachusetts General Hospital, Boston, USA
J Clin Psychiatry 71:e31. 2010..An agent such as folate, which is a naturally occurring B vitamin and is necessary for the synthesis of the trimonoamine neurotransmitters implicated in depression, may enhance the effects of a traditional antidepressant... - Predictors of stable personality disorder diagnoses in outpatients with remitted depressionAmy Farabaugh
Depression and Clinical Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
J Nerv Ment Dis 190:248-56. 2002.... - The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatientsAmy Farabaugh
Depression Clinical and Research Program, Massachusetts General Hospital, MA WAC 812, USA
Int Clin Psychopharmacol 20:87-91. 2005..In conclusion, the presence of early improvement on the HAMD-17 item concerning fatigue and general somatic symptoms is significantly predictive of achieving remission at endpoint with active study treatment but not with placebo... - S-adenosyl-L-methionine (SAMe) as an adjunct for resistant major depressive disorder: an open trial following partial or nonresponse to selective serotonin reuptake inhibitors or venlafaxineJonathan E Alpert
Depression Clinical and Research Program, Massachusetts General Hospital, Department of Psychiatry, Harvard Medical School, Boston, MA 02114, USA
J Clin Psychopharmacol 24:661-4. 2004..The purpose of this open trial was to evaluate the safety, tolerability, and efficacy of oral S-adenosyl-L-methionine as an antidepressant adjunct among partial and nonresponders to serotonin reuptake inhibitors or venlafaxine... - The pharmacologic management of SSRI-induced side effects: a survey of psychiatristsChristina M Dording
Depression Clinical and Research Group, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Ann Clin Psychiatry 14:143-7. 2002..In our opinion, this practice may reflect the relative lack of research studies on the role of adjunctive treatments in the management of SSRI-induced side effects and/or the tendency to favor monotherapy over polypharmacy... - Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 2: predictors of relapse during the continuation phase of pharmacotherapyGeorge I Papakostas
Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
J Clin Psychiatry 65:1096-8. 2004.... - Serum folate, vitamin B12, and homocysteine in major depressive disorder, Part 1: predictors of clinical response in fluoxetine-resistant depressionGeorge I Papakostas
Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
J Clin Psychiatry 65:1090-5. 2004.... - Integrating psychiatry and primary care improves acceptability to mental health services among Chinese AmericansAlbert Yeung
Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
Gen Hosp Psychiatry 26:256-60. 2004..3, P<.001) in the previous 12 months. Integrating psychiatry and primary care is effective in improving access to mental health services and in increasing treatment engagement among low-income immigrant Chinese Americans... - Prevalence of major depressive disorder among Chinese-Americans in primary careAlbert Yeung
Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA, USA
Gen Hosp Psychiatry 26:24-30. 2004..6% +/- 0.06. MDD is common among Asian-Americans in primary care settings. The prevalence of MDD is comparable to or higher than those found in the U.S. nonminority populations... - Quality of life assessments in major depressive disorder: a review of the literatureGeorge I Papakostas
Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
Gen Hosp Psychiatry 26:13-7. 2004..Exploring the impact of these modalities on psychosocial function and quality of life in MDD are necessary to help translate clinical response into restoration of psychosocial function and to thus further improve the standard of care... - Serotonin transporter polymorphisms and adverse effects with fluoxetine treatmentRoy H Perlis
Department of Psychiatry, Massachusetts General Hospital, Boston 02114, USA
Biol Psychiatry 54:879-83. 2003..This study investigated a possible association with treatment-emergent insomnia or agitation... - Serum cholesterol and serotonergic function in major depressive disorderGeorge I Papakostas
Depression Clinical and Research Program, Department of Psychiatry, Harvard Medical School, Massachusetts General Hospital, 15 Parkman Street, WAC 812, Boston, MA 02114, USA
Psychiatry Res 118:137-45. 2003.... - The relationship between serum folate, vitamin B12, and homocysteine levels in major depressive disorder and the timing of improvement with fluoxetineGeorge I Papakostas
Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital Harvard Medical School, Boston, MA 02114, USA
Int J Neuropsychopharmacol 8:523-8. 2005..05). In conclusion, low serum folate levels were found to be associated with a delayed onset of clinical improvement during treatment with fluoxetine in MDD by, on average, 1.5 wk... - An open study of triiodothyronine augmentation of selective serotonin reuptake inhibitors in treatment-resistant major depressive disorderDan V Iosifescu
Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston 02114, USA
J Clin Psychiatry 66:1038-42. 2005..In an open trial, we investigated the efficacy of triiodothyronine (T(3)) adjuvant to selective serotonin reuptake inhibitors (SSRIs) in subjects with major depressive disorder (MDD) resistant to SSRI treatment... - Differences in cognitive factors between "true drug" versus "placebo pattern" response to fluoxetine as defined by pattern analysisAmy H Farabaugh
Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, USA USA
Hum Psychopharmacol 21:221-5. 2006..This study examines the relationship between cognitive factors and TDR and PPR to fluoxetine... - Folinic acid (Leucovorin) as an adjunctive treatment for SSRI-refractory depressionJonathan E Alpert
Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston 02114, USA
Ann Clin Psychiatry 14:33-8. 2002..Leucovorin appears to be modestly effective as an adjunct among SSRI-refractory depressed individuals with normal folate levels. The application of leucovorin as an adjunct in the setting of refractory depression deserves further study... - The combination of duloxetine and bupropion for treatment-resistant major depressive disorderGeorge I Papakostas
Department of Psychiatry, Depression Clinical and Research Program, Massachusetts General Hospital, Boston, 02114, USA
Depress Anxiety 23:178-81. 2006..Although preliminary, these results suggest a possible role for the combination of duloxetine and bupropion for TRD... - Outcomes of recognizing depressed Chinese American patients in primary careAlbert Yeung
Depression Clinical and Research Program, Massachusetts General Hospital, Harvard Medical School, 15 Parkman Street, Boston, Massachusetts 02114, USA
Int J Psychiatry Med 35:213-24. 2005..This study aims to examine the effect of identifying Chinese American patients as having major depressive disorder (MDD) to their primary care physicians (PCPs) on the latter's attention given to the treatment of depression... - An open study of olanzapine and fluoxetine for psychotic major depressive disorder: interim analysesJohn D Matthews
Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston 02114, USA
J Clin Psychiatry 63:1164-70. 2002..The aim of this study was to assess, by interim analyses, the efficacy of the atypical antipsychotic agent olanzapine in combination with the selective serotonin reuptake inhibitor antidepressant agent fluoxetine... - Anger attacks in major depressive disorder and serum levels of homocysteineRenerio Fraguas
Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 02114, USA
Biol Psychiatry 60:270-4. 2006..Increased levels of homocysteine have been associated with anger and depression separately. We investigated the association of anger attacks in major depressive disorder (MDD) with serum levels of homocysteine... - Relationships between major depressive disorder and comorbid anxiety and personality disordersAmy Farabaugh
Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
Compr Psychiatry 46:266-71. 2005.... - A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorderMaurizio Fava
Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
J Clin Psychopharmacol 25:441-7. 2005..This study looks to compare the antidepressant efficacy and safety of a standardized extract of St John's wort with both placebo and fluoxetine... - Dysfunctional attitudes and personality disorder comorbidity during long-term treatment of MDDAmy Farabaugh
Depression Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital, Boston, Massachusetts 02114, USA
Depress Anxiety 24:433-9. 2007..This finding suggests that dysfunctional attitudes that persist beyond remission of MDD may be a marker for certain personality disorders that are stable across long-term treatment... - SAMe and sexual functioningC M Dording
Depression Clinical and Research Program, Massachusetts General Hospital, Department of Psychiatry, Massachusetts General Hospital, 1 Bowdoin Square, 6th Floor, Boston, MA 02114, USA
Eur Psychiatry 27:451-4. 2012..Consequently, it is vital to develop novel treatments that target antidepressant-induced sexual dysfunction... - Does psychiatry residency training reflect the "real world" of psychiatry practice? A survey of residency graduatesTimothy Petersen
Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
Acad Psychiatry 31:281-9. 2007..The authors determine whether Massachusetts General Hospital's residency graduates believed their training reflected their current practice activities... - Effects of S-adenosylmethionine augmentation of serotonin-reuptake inhibitor antidepressants on cognitive symptoms of major depressive disorderY Levkovitz
Psychiatry Department, Shalvata Mental Health Center, Tel Aviv University, Hamargoa 4, POB 94, Tel Aviv, Israel
Eur Psychiatry 27:518-21. 2012.... - Functioning and interpersonal relationships as predictors of response in treatment-resistant depressionGeorge I Papakostas
Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA, USA
Compr Psychiatry 44:44-50. 2003..Beyond a history of nonresponse to antidepressants, long-term occupational function may be a predictor of outcome in the treatment of TRD... - Omega-3 fatty acids: evidence basis for treatment and future research in psychiatryMarlene P Freeman
Women s Mental Health Program, Department of Psychiatry, University of Arizona College of Medicine, Tucson 85724 5002, USA
J Clin Psychiatry 67:1954-67. 2006..To determine if the available data support the use of omega-3 essential fatty acids (EFA) for clinical use in the prevention and/or treatment of psychiatric disorders... - Clinical features and functioning of patients with minor depressionRobert H Howland
Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
Psychother Psychosom 77:384-9. 2008..The two essential features of minor depression are that it has fewer symptoms than major depression and that it is less chronic than dysthymia. This study describes the clinical features and functioning of outpatients with minor depression... - Hypericum extract in patients with MDD and reversed vegetative signs: re-analysis from data of a double-blind, randomized trial of hypericum extract, fluoxetine, and placeboHarald Murck
Lichtwer Pharma GmbH, Berlin, Germany
Int J Neuropsychopharmacol 8:215-21. 2005..These data are based on a small sample size and must be considered tentative. A characterization of vegetative features of patients with depression could lead to an overall increased effect size in the treatment with HE... - Acupuncture for major depressive disorder: has its efficacy been disproved?Albert Yeung
J Clin Psychiatry 68:1617; author reply 1617-8. 2007
Research Grants
- Omega-3 Fatty Acids in the Treatment of DepressionDavid Mischoulon; Fiscal Year: 2005..It is hoped that this project will provide the critical fund of basic knowledge and practical experience necessary to aid the candidate in becoming an independent investigator. ..
- Omega-3 Fatty Acids for Treatment of Major DepressionDavid Mischoulon; Fiscal Year: 2007..e. integrates biological findings with treatment in order to have a direct impact on the clinical practice of psychiatry. ..
- Omega-3 Fatty Acids for Treatment of Major DepressionDavid Mischoulon; Fiscal Year: 2009..e. integrates biological findings with treatment in order to have a direct impact on the clinical practice of psychiatry. ..
- Omega-3 Fatty Acids for Treatment of Major DepressionDavid Mischoulon; Fiscal Year: 2010..e. integrates biological findings with treatment in order to have a direct impact on the clinical practice of psychiatry. ..